Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy

High-affinity IL-2Rα expressed by Tregs mitigates the potential of IL-2 use in cancer therapy. Here, the authors fuse IL-2 with an NKDG2 binding domain, and show that it induces IL-2 signalling selectively in NKG2D+cells, delaying tumour growth in mice without the side effects of conventional IL-2 t...

Full description

Bibliographic Details
Main Authors:	Reza Ghasemi, Eric Lazear, Xiaoli Wang, Saeed Arefanian, Alexander Zheleznyak, Beatriz M. Carreno, Ryuji Higashikubo, Andrew E. Gelman, Daniel Kreisel, Daved H. Fremont, Alexander Sasha Krupnick
Format:	Article
Language:	English
Published:	Nature Publishing Group 2016-09-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/ncomms12878

id	doaj-556e5f18a8074910ad3823823e1bf265
record_format	Article
spelling	doaj-556e5f18a8074910ad3823823e1bf2652021-05-11T10:46:03ZengNature Publishing GroupNature Communications2041-17232016-09-017111510.1038/ncomms12878Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapyReza Ghasemi0Eric Lazear1Xiaoli Wang2Saeed Arefanian3Alexander Zheleznyak4Beatriz M. Carreno5Ryuji Higashikubo6Andrew E. Gelman7Daniel Kreisel8Daved H. Fremont9Alexander Sasha Krupnick10Department of Surgery, Washington University in St LouisDepartment of Pathology & Immunology, Washington University in St LouisDepartment of Pathology & Immunology, Washington University in St LouisDepartment of Surgery, Washington University in St LouisDepartment of Surgery, Washington University in St LouisDepartment of Medicine, Washington University in St LouisDepartment of Surgery, Washington University in St LouisDepartment of Surgery, Washington University in St LouisDepartment of Surgery, Washington University in St LouisDepartment of Pathology & Immunology, Washington University in St LouisDepartment of Surgery, Washington University in St LouisHigh-affinity IL-2Rα expressed by Tregs mitigates the potential of IL-2 use in cancer therapy. Here, the authors fuse IL-2 with an NKDG2 binding domain, and show that it induces IL-2 signalling selectively in NKG2D+cells, delaying tumour growth in mice without the side effects of conventional IL-2 therapy.https://doi.org/10.1038/ncomms12878
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Reza Ghasemi Eric Lazear Xiaoli Wang Saeed Arefanian Alexander Zheleznyak Beatriz M. Carreno Ryuji Higashikubo Andrew E. Gelman Daniel Kreisel Daved H. Fremont Alexander Sasha Krupnick
spellingShingle	Reza Ghasemi Eric Lazear Xiaoli Wang Saeed Arefanian Alexander Zheleznyak Beatriz M. Carreno Ryuji Higashikubo Andrew E. Gelman Daniel Kreisel Daved H. Fremont Alexander Sasha Krupnick Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy Nature Communications
author_facet	Reza Ghasemi Eric Lazear Xiaoli Wang Saeed Arefanian Alexander Zheleznyak Beatriz M. Carreno Ryuji Higashikubo Andrew E. Gelman Daniel Kreisel Daved H. Fremont Alexander Sasha Krupnick
author_sort	Reza Ghasemi
title	Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
title_short	Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
title_full	Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
title_fullStr	Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
title_full_unstemmed	Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
title_sort	selective targeting of il-2 to nkg2d bearing cells for improved immunotherapy
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2016-09-01
description	High-affinity IL-2Rα expressed by Tregs mitigates the potential of IL-2 use in cancer therapy. Here, the authors fuse IL-2 with an NKDG2 binding domain, and show that it induces IL-2 signalling selectively in NKG2D+cells, delaying tumour growth in mice without the side effects of conventional IL-2 therapy.
url	https://doi.org/10.1038/ncomms12878
work_keys_str_mv	AT rezaghasemi selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT ericlazear selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT xiaoliwang selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT saeedarefanian selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT alexanderzheleznyak selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT beatrizmcarreno selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT ryujihigashikubo selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT andrewegelman selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT danielkreisel selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT davedhfremont selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy AT alexandersashakrupnick selectivetargetingofil2tonkg2dbearingcellsforimprovedimmunotherapy
_version_	1721447611754348544

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy

Similar Items